Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Revolution Medicines (RVMD) Interest Expenses (2019 - 2025)

Revolution Medicines (RVMD) has 5 years of Interest Expenses data on record, last reported at $11.4 million in Q3 2025.

  • For Q3 2025, Interest Expenses changed N/A year-over-year to $11.4 million; the TTM value through Dec 2025 reached $11.4 million, up 306.84%, while the annual FY2025 figure was $24.2 million, 858.5% up from the prior year.
  • Interest Expenses reached $11.4 million in Q3 2025 per RVMD's latest filing, up from $2.8 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $11.4 million in Q3 2025 and bottomed at $12000.0 in Q1 2021.
  • Average Interest Expenses over 3 years is $4.7 million, with a median of $2.8 million recorded in 2024.
  • The widest YoY moves for Interest Expenses: up 42.86% in 2021, down 42.86% in 2021.
  • A 3-year view of Interest Expenses shows it stood at $12000.0 in 2021, then skyrocketed by 23308.33% to $2.8 million in 2024, then soared by 306.84% to $11.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $11.4 million in Q3 2025, $2.8 million in Q1 2024, and $12000.0 in Q1 2021.